Estimating Cancer Latency Times Using a Weibull Model

Table 2

Approximate latency times from cancer initiation to diagnosis by cancer site.

Cancer site	Sample size	5-year survival rate	Years from onset to diagnosis	Median age at cancer onset
Acute lymphocytic leukemia	3,701	21.5%	35.7	8.3
Acute monocytic leukemia	1,118	8.8%	15.7	47.3
Acute myeloid leukemia	17,733	12.3%	25.7	39.3
Aleukemic, subleukemic, and NOS	1,785	15.5%	19.3	52.7
Ascending colon	30,038	46.2%	56.8	16.2
Brain	36,828	9.9%	21.9	36.1
Breast	378,477	54.3%	16.3	43.7
Cecum	46,552	36.7%	52.4	20.6
Chronic lymphocytic leukemia	24,466	15.9%	2.2	67.8
Chronic myeloid leukemia	10,498	9.6%	5.1	58.9
Descending colon	13,634	42.4%	52.4	16.6
Esophagus	26,504	6.0%	9.4	56.6
Floor of mouth	5,260	31.5%	21.9	40.1
Gallbladder	8,105	9.6%	25.2	46.8
Gum and other mouth	9,834	37.5%	28.7	34.3
Hypopharynx	5,241	4.8%	9.6	53.4
Kidney and renal pelvis	56,093	33.2%	48.2	14.8
Large intestine, NOS	9,225	19.0%	37.9	36.1
Larynx	22,545	43.1%	35.4	27.6
Liver	22,316	6.0%	10.8	53.2
Lung and bronchus	358,750	6.4%	13.6	53.4
Myeloma	33,252	3.8%	3.6	65.4
NHL-nodal	70,558	27.5%	26.5	37.5
Nasopharynx	4,435	32.4%	25.2	29.8
Nose, nasal cavity, and middle ear	4,062	30.6%	23.0	40.0
Oropharynx	1,763	18.6%	12.3	48.7
Other biliary	8,811	7.4%	16.1	54.9
Other digestive organs	2,145	7.3%	6.6	63.4
Other myeloid/monocytic leukemia	1,424	13.1%	10.5	61.5
Other oral cavity and pharynx	1,722	14.9%	16.9	46.1
Ovary	47,721	25.8%	44.1	17.9
Pancreas	65,835	1.8%	8.4	60.6
Peritoneum, omentum, and mesentery	2,622	11.5%	9.2	56.8
Pleura	5,153	2.5%	4.5	65.5
Rectosigmoid junction	28,603	35.8%	36.6	31.4
Rectum	60,514	34.3%	29.8	37.2
Retroperitoneum	2,433	12.0%	23.1	37.9
Sigmoid colon	69,135	44.3%	52.1	16.9
Small intestine	7,957	25.9%	26.0	38.0
Splenic flexure	7,259	31.7%	42.4	27.6
Stomach	54,521	11.9%	22.3	46.7
Tongue	14,102	33.8%	26.7	33.3
Tonsil	7,429	27.5%	18.9	39.1
Transverse colon	18,325	37.8%	57.0	15.0